NOTCH1 mediates a switch between two distinct secretomes during senescence by Hoare, Matthew et al.
 
 
NOTCH1 mediates a switch between two distinct
secretomes during senescence
Hoare, Matthew; Ito, Yoko; Kang, Tae-Won; Weekes, Michael P; Matheson, Nicholas J;
Patten, Daniel; Shetty, Shishir; Parry, Aled J; Menon, Suraj; Salama, Rafik; Antrobus, Robin;
Tomimatsu, Kosuke; Howat, William; Lehner, Paul J; Zender, Lars; Narita, Masashi
DOI:
10.1038/ncb3397
License:
None: All rights reserved
Document Version
Peer reviewed version
Citation for published version (Harvard):
Hoare, M, Ito, Y, Kang, T-W, Weekes, MP, Matheson, NJ, Patten, D, Shetty, S, Parry, AJ, Menon, S, Salama, R,
Antrobus, R, Tomimatsu, K, Howat, W, Lehner, PJ, Zender, L & Narita, M 2016, 'NOTCH1 mediates a switch
between two distinct secretomes during senescence', Nature Cell Biology, vol. 18, no. 9, pp. 979-92.
https://doi.org/10.1038/ncb3397
Link to publication on Research at Birmingham portal
Publisher Rights Statement:
Final Version of Record available at: http://dx.doi.org/10.1038/ncb3397
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Feb. 2019
 1
NOTCH1 mediates a switch between two distinct secretomes during 1 
senescence 2 
 3 
Matthew Hoare1,2, Yoko Ito1, Tae-Won Kang3, Michael P. Weekes2,4, Nicholas 4 
J. Matheson2,4, Daniel A. Patten5, Shishir Shetty5, Aled J. Parry1, Suraj 5 
Menon1, Rafik Salama1, Robin Antrobus4, Kosuke Tomimatsu1, William 6 
Howat1, Paul J. Lehner2,4, Lars Zender3 and Masashi Narita1,* 7 
 8 
1University of Cambridge, Cancer Research UK Cambridge Institute, 9 
Robinson Way, Cambridge, CB2 0RE, UK. 10 
2University of Cambridge, Department of Medicine, Addenbrooke’s Hospital, 11 
Cambridge, CB2 0QQ, UK. 12 
3Division of Translational Gastrointestinal Oncology, Dept. of Internal 13 
Medicine I, University Hospital Tuebingen, Otfried-Mueller-Strasse 12, 72076 14 
Tuebingen, Germany & Translational Gastrointestinal Oncology Group within 15 
the German Consortium for Translational Cancer Research (DKTK), German 16 
Cancer Research Center (DKFZ), Heidelberg, Germany. 17 
4University of Cambridge, Cambridge Institute for Medical Research, 18 
Addenbrooke's Hospital, Cambridge, CB2 0XY, UK. 19 
5National Institute of Health Research (NIHR) Birmingham Liver Biomedical 20 
Research Unit (BRU), Centre for Liver Research, University of Birmingham, 21 
Birmingham, B15 2TT, UK. 22 
*Correspondence: masashi.narita@cruk.cam.ac.uk  23 
 24 
 25 
  26 
 2
ABSTRACT 27 
Senescence, a persistent form of cell cycle arrest, is often associated with a 28 
diverse secretome, which provides complex functionality for senescent cells 29 
within the tissue microenvironment. We show that oncogene-induced 30 
senescence (OIS) is accompanied by a dynamic fluctuation of NOTCH1 31 
activity, which drives a TGF-β-rich secretome, whilst suppressing the 32 
senescence-associated pro-inflammatory secretome through inhibition of 33 
C/EBPβ. NOTCH1 and NOTCH1-driven TGF-β contribute to ‘lateral induction 34 
of senescence’ through a juxtacrine NOTCH-JAG1 pathway. In addition, 35 
NOTCH1 inhibition during senescence facilitates upregulation of pro-36 
inflammatory cytokines, promoting lymphocyte recruitment and senescence 37 
surveillance in vivo. Because enforced activation of NOTCH1 signalling 38 
confers a near mutually exclusive secretory profile compared to typical 39 
senescence, our data collectively indicate that the dynamic alteration of 40 
NOTCH1 activity during senescence dictates a functional balance between 41 
these two distinct secretomes: one representing TGF-β and the other pro-42 
inflammatory cytokines, highlighting that NOTCH1 is a temporospatial 43 
controller of secretome composition. 44 
 45 
 46 
  47 
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 48 
INTRODUCTION 49 
Cellular senescence is an autonomous tumour suppressor mechanism, 50 
whereby various triggers drive a stable proliferative arrest. Senescence is 51 
accompanied by diverse biochemical changes including upregulation of CDK 52 
inhibitors, the accumulation of senescence-associated β-galactosidase (SA-β-53 
gal) activity, and expression of a wide variety of secretory proteins1,2. These 54 
features of senescence have been recapitulated by in vivo models, including 55 
both pathological and physiological contexts3. 56 
 57 
Senescent cells have profound non-autonomous functionality in the tissue 58 
microenvironment through the senescence-associated secretory phenotype 59 
(SASP)2. Previous studies have demonstrated heterogeneous effects of the 60 
SASP upon tumorigenesis. The SASP can reinforce the senescent phenotype 61 
in both an autocrine and paracrine fashion4-6 and activate immune clearance 62 
of senescent cells7-9 from tissues, thereby contributing to tumour suppression. 63 
Some tumorigenic activities of SASP have also been shown through 64 
promoting cellular growth and epithelial–mesenchymal transition in 65 
neighbouring immortalised or transformed epithelial cells10,11. In addition, 66 
SASP components, among others, include inflammatory cytokines and matrix-67 
modifying enzymes, which play key roles in the clearance of senescent or 68 
damaged cells and resolution of tissue injury, respectively. Thus, it is 69 
conceivable that both the relative and absolute expression of SASP 70 
components is dynamic and under tight regulation. However, the basis for the 71 
regulation of different SASP components or controlling the net function of the 72 
SASP is unclear.   73 
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 74 
NOTCH signalling is evolutionarily conserved and involved in a wide range of 75 
developmental and physiological processes, controlling cell-fate specification 76 
and stem cell homeostasis12 In addition, alterations of the NOTCH pathway 77 
have been linked to stress response and tumorigenesis, where it can be 78 
oncogenic or tumour suppressive depending on tissue and context13. There 79 
are four NOTCH receptors, which bind the Jagged (JAG) and Delta-like family 80 
of ligands12. Upon ligand binding the NOTCH receptors undergo a series of 81 
proteolytic cleavage events liberating the intracellular domain (ICD), which 82 
subsequently translocates to the nucleus to bind a multi-molecular complex, 83 
including both the DNA-binding protein, RBP-J and Mastermind-like (MAML) 84 
co-activators12 and drive transcription of NOTCH-target genes, such as the 85 
HES/HEY family of transcription factors (TFs). Importantly, NOTCH ligands 86 
are also transmembrane proteins; thus, signalling is thought to be restricted to 87 
adjacent cells through juxtacrine interaction, and the role of NOTCH in 88 
autocrine or paracrine signalling through secreted factors remains unclear.  89 
 90 
Through a quantitative cell surface proteome of oncogene-induced senescent 91 
(OIS) cells and subsequent validation, we have identified a global 92 
upregulation of NOTCH1 that is accompanied by dynamic alteration of its 93 
downstream activity during senescence. We describe how NOTCH1 functions 94 
as a master regulator of SASP composition through a temporal and functional 95 
switch between two distinct secretomes, representing TGF-β or pro-96 
inflammatory cytokines, in part through downregulation of C/EBPβ. We show 97 
that inhibiting Notch signalling promotes clearance of OIS cells in the liver, 98 
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implying a unique therapeutic opportunity to target senescent cells through 99 
modulation of immune surveillance. 100 
 101 
RESULTS 102 
Plasma membrane proteome in OIS 103 
To gain a better understanding of the phenotype of OIS cells, particularly 104 
potential mediators of non-cell-autonomous signalling, we conducted a 105 
proteomic screen of plasma membrane (PM) surface proteins utilising a 106 
quantitative SILAC approach14 in IMR90 human diploid fibroblasts (HDFs) 107 
expressing oncogenic HRASG12V in a 4-hydroxytamoxifen (4OHT)-inducible 108 
form (ER:HRASG12V) (Fig. 1a, Supplementary Fig. 1A)15. We identified 109 
peptides from 1502 independent proteins with. enrichment for localisation in 110 
PM or extracellular compartments in Gene Ontology (GO) analysis (Fig. 1b). 111 
Of the 1502 proteins, 521 were identified with ‘high confidence’ (see 112 
METHODS) with 32 and 135 significantly up and downregulated respectively 113 
in HRASG12V-induced senescent (RIS) cells (Fig. 1c, Supplementary Table 1). 114 
 115 
To validate our proteomic findings, we compared the RIS-associated PM 116 
changes with transcriptomic data and identified a significant positive 117 
correlation between mRNA and protein changes during RIS (Supplementary 118 
Fig. 1B).  119 
 120 
NOTCH1 is upregulated in OIS 121 
To understand signalling networks involving senescence-associated PM 122 
proteins we conducted network enrichment analysis, utilising both 123 
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transcriptomic and proteomic data. The highest enriched network contained 124 
the NOTCH1 receptor as a major network hub and its canonical targets 125 
(HES1, HEY1, and HEYL) and binding partners (RBPJ and MAML3) (Fig. 1c, 126 
Supplementary Fig. 1C).  127 
 128 
Utilising flow cytometry we confirmed the substantial upregulation of cell 129 
surface NOTCH1 during senescence induced by different triggers (oncogenic 130 
MEK or DNA damage) or RIS in different HDFs (Fig. 1d, Supplementary Fig. 131 
1D, E). In contrast, bypass of RIS through co-expression of the adenoviral 132 
oncoprotein, E1A failed to up-regulate cell surface NOTCH1 on IMR90 cells 133 
(Fig. 1d). Although the NOTCH pathway has recently been implicated in 134 
senescence16-18, its functional relevance is unclear. 135 
 136 
NOTCH1 signalling is dynamically regulated during senescence 137 
We next investigated the temporal changes of cell surface NOTCH1 and its 138 
downstream activity after ER:HRASG12V induction. In this system, senescence 139 
develops progressively from an initial mitotic phase (~d1) to senescence 140 
establishment (~d6) (Supplementary Fig. 1A)15. After a slight reduction at the 141 
mitotic phase, cell surface NOTCH1 continually increased during RIS (Fig. 142 
2a). However, the cleaved, active NOTCH1 intracellular domain (N1ICD) and 143 
the canonical NOTCH1-target HES1 were transiently upregulated during the 144 
transition to senescence, but returned to near basal level at full senescence 145 
(Fig. 2b). The transient activation of NOTCH1 signalling, despite increased 146 
cell surface NOTCH1, was also observed during DNA damage-induced 147 
senescence (DDIS) (Fig. 2c, Fig. 1d right)19.  148 
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 149 
Characterised SASP components include multiple pro-inflammatory cytokines, 150 
such as IL-1, IL-6 and IL-86,11,20,21. More recently, TGF-β ligands have been 151 
identified as SASP components, which are involved in senescence induction, 152 
in part through inducing p15 and p214,5. IL-6 and IL-8 were primarily 153 
upregulated at full senescence. However, we found a transient induction of 154 
TGF-β ligands during both RIS and DDIS, reminiscent of the N1ICD 155 
expression pattern (Fig. 2b, c, Supplementary Fig. 2A), suggesting that 156 
NOTCH signalling temporally correlates with the reciprocal induction of TGF-β 157 
and pro-inflammatory cytokines during senescence.  158 
 159 
NOTCH1 reciprocally regulates TGF-β and pro-inflammatory cytokines 160 
To examine the relationship between NOTCH1 and regulation of secretory 161 
factors during RIS, we first introduced a dominant negative form of MAML1, 162 
fused to mVenus (dnMAML1-mVenus), into ER:RASG12V-expressing IMR90 163 
cells. At d3 after ER:RASG12V induction, expression of dnMAML1 led to 164 
minimal effect upon proliferation, but completely blocked the induction of 165 
HES1 (Fig. 2d). This inhibition of NOTCH signalling significantly reduced the 166 
upregulation of TGFB1, suggesting that NOTCH is upstream of HRASG12V-167 
driven TGF-β induction (Fig. 2d). Conversely, upregulation of pro-168 
inflammatory cytokines (IL-8, IL1A, and IL1B) was enhanced by dnMAML1, 169 
suggesting that activated NOTCH1, during senescence transition, negatively 170 
regulates the expression of pro-inflammatory cytokines. Similar results were 171 
obtained pharmacologically with DAPT, a gamma secretase inhibitor, which 172 
blocks cleavage and release of the N1ICD (Supplementary Fig. 2B). Notably, 173 
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the endogenous levels of N1ICD were modestly increased in the presence of 174 
dnMAML1 regardless of HRASG12V-induction (Figure 2d). This is consistent 175 
with previous studies showing that N1ICD levels are controlled by negative 176 
feedback through MAML-dependent proteasomal degradation, providing a 177 
potential mechanism for the decoupling of surface NOTCH1 and N1ICD levels 178 
22.  179 
 180 
We next introduced a doxycycline-inducible N1ICD-FLAG system into IMR90 181 
cells (Supplementary Fig. 2C). Restoration of N1ICD at the late phase of RIS 182 
(d6) led to a dose-dependent decrease in IL1A, IL1B and IL-8 expression and 183 
a dose-dependent increase in TGFB1 expression, with minimal impact on 184 
senescence arrest (Fig. 2e). Therefore, during RIS, the dynamic alteration of 185 
NOTCH1 controls the temporally reciprocal pattern of TGF-β1 and pro-186 
inflammatory cytokines and manipulating NOTCH signalling allows for SASP 187 
modulation with senescence arrest being maintained. 188 
 189 
Enforced activation of NOTCH1 induces a unique senescence 190 
phenotype in HDFs 191 
Consistent with recent reports16-18, expression of ectopic N1ICD drove a 192 
senescence-like morphological change with stable cell cycle arrest, although 193 
accumulation of SA-β-gal activity was relatively modest (Fig. 3a, b, 194 
Supplementary Fig. 2D, E). Note, proliferative arrest was maintained even 195 
after removal of ectopic N1ICD, the hallmark of senescence (Supplementary 196 
Fig. 2E). Overexpression of N1ICD was sufficient for reduction of basal IL-8 197 
levels as well as induction of TGF-β1 and its downstream effector 198 
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phosphorylated SMAD3 (Fig. 3a, c, d). Thus, ectopic N1ICD induces 199 
senescence that is distinct from RIS or DDIS, particularly in its SASP 200 
composition. 201 
 202 
To understand the broader implications of NOTCH1 in the control of 203 
secretome composition, we performed mRNA-seq analysis of senescent 204 
IMR90 cells driven by HRASG12V, DNA damage, or N1ICD. Transcriptional 205 
profiling of secretory factors of RIS and DDIS shared large clusters (Fig. 3e). 206 
Gene Set Enrichment Analysis (GSEA) showed that all types of senescence 207 
shared a common cell-cycle signature (Supplementary Fig. 3A). However, the 208 
secretome expression profile of N1ICD-induced senescence (NIS) exhibited 209 
an almost mutually exclusive pattern with RIS and DDIS, particularly in those 210 
shared clusters (Fig. 3e). Many secretory factors that have been associated 211 
with RIS or DDIS, such as pro-inflammatory cytokines and matrix 212 
metalloproteinases (MMP1/3/10), were repressed by ectopic N1ICD. 213 
Downregulated secretory factors at d6 of RIS, including TGF-β ligands 214 
(TGFB1/2/3) were upregulated by ectopic N1ICD in IMR90 cells. GSEA 215 
revealed a close association of TGF-β1 signatures with NIS (Supplementary 216 
Fig. 3B). To understand the relative dominance of RAS and N1ICD upon the 217 
secretome composition we analysed secretome transcriptional data from 218 
IMR90 cells undergoing RIS, NIS or expressing both RAS and N1ICD 219 
(N+RIS). Unsupervised clustering revealed the similarity between NIS and 220 
N+RIS secretomes, where ectopic N1ICD mostly overcame the RIS pattern 221 
(Supplementary Fig. 3C). Interestingly, such dominance of NOTCH over RAS 222 
also applied to GLB1, encoding the lysosomal enzyme responsible for SA-β-223 
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Gal activity23, potentially explaining the modest SA-β-Gal activity of NIS (Fig. 224 
3b). Altogether, our data suggest that NIS and RIS are associated with 225 
reciprocal secretory profiles, and that dynamic NOTCH1 activity during 226 
senescence determines the balance between two extremities: one 227 
representing TGF-β ligands and the other representing ‘classical’ SASP 228 
components including pro-inflammatory cytokines. 229 
 230 
NOTCH1-driven cell-autonomous senescence is partly dependent on 231 
TGF-β signalling 232 
To understand how N1ICD induces senescence, we expressed N1ICD in the 233 
presence or absence of inhibitors of the TGF-β receptor (TGFBR1). Inhibition 234 
of TGF-β signalling prevented upregulation of TGF-β targets, p15 and TGFB-235 
induced (TGFBI), in N1ICD-expressing cells, and partly rescued the anti-236 
proliferative effect of N1ICD (Fig. 3f, Supplementary Fig. 4A, left). Similar 237 
results were also obtained by expression of a dominant negative form of 238 
SMAD4 (dnSMAD4) (Supplementary Fig. 4B, left)24. Importantly, recombinant 239 
TGF-βs alone had no anti-proliferative effect on IMR90 cells (Supplementary 240 
Fig. 4C and D), suggesting that NOTCH-driven TGF-β signalling contributes 241 
to senescence cooperatively with other NOTCH1-downstream factor(s), as yet 242 
to be elucidated.  243 
 244 
Non-cell-autonomous effects of NOTCH1 on normal cells 245 
To investigate the non-cell-autonomous effects of differing forms of 246 
senescence, we set up co-culture experiments of mRFP-labelled, otherwise 247 
normal, IMR90 cells with senescent IMR90 cells induced by N1ICD, 248 
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HRASG12V or DNA damage. To avoid confounding effects of the ‘TGF-β 249 
phase’ of SASP during RIS and DDIS, senescence was pre-induced for 4 250 
days before co-culture. We found that mRFP-labelled cells co-cultured with 251 
NIS, but not late phase RIS or DDIS cells, at least in IMR90 cells, underwent 252 
a growth arrest, suggesting a key role for the NOTCH1-driven secretome in 253 
the transmission of senescence (Fig. 4a).  254 
 255 
To understand signalling pathways that might underpin N1ICD-mediated non-256 
autonomous growth arrest, we co-cultured NIS and mRFP-IMR90 cells for 72 257 
hours prior to flow sorting and then analysing gene expression in both cell 258 
populations. Consistent with N1ICD-mediated induction of TGF-β ligands in 259 
the mono-culture experiments (Fig. 3c-e), both N1ICD-expressing and mRFP-260 
cells exhibited upregulation of the TGF-β targets, p15/CDKN2B and TGFBI 261 
(Fig. 4b). Similarly to autonomous NOTCH1 activation, TGFBR1 inhibitors or 262 
dnSMAD4 partially rescued the non-autonomous growth arrest in mRFP-cells 263 
when co-cultured with N1ICD-expressing cells (Fig. 4c, Supplementary Fig. 264 
4A, B).  265 
 266 
To further examine whether N1ICD-expressing cells induce senescence in 267 
neighbouring cells, we took advantage of the difference in the drug selection 268 
markers of retroviral vectors expressing either N1ICD (or control vector) or 269 
mRFP: after co-culturing N1ICD-expressing cells (hygromycin resistant) and 270 
mRFP-expressing cells (puromycin resistant), cells were incubated with 271 
puromycin for 2 days to remove N1ICD-expressing cells (Fig. 4d). After 272 
additional culture for 5 days, mRFP cells that had been co-cultured with 273 
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N1ICD-expressing cells, but not with vector-expressing cells, exhibited a 274 
senescent phenotype (Fig. 4d, e). Importantly, this phenotype was maintained 275 
even after the removal of the signal-sending cells, indicating that the N1ICD-276 
expressing cells transmitted a senescent phenotype to the neighbouring cells.  277 
 278 
N1ICD-induced ‘lateral induction’ of senescence 279 
The role of NOTCH in biological patterning during development is attributed to 280 
processes termed ‘lateral inhibition’ and ‘lateral induction’25: NOTCH-281 
mediated downregulation of NOTCH ligands in the same cells will negatively 282 
regulate NOTCH signalling in neighbouring cells (lateral inhibition), whereas 283 
NOTCH-mediated upregulation of NOTCH ligands will positively regulate 284 
NOTCH activity in neighbouring cells (lateral induction)26. 285 
 286 
Interestingly, activation of downstream NOTCH signalling was observed not 287 
only in the N1ICD-expressing cells, but also in the co-cultured target cells with 288 
increased expression of HES1 (Fig. 4b). In addition, basal levels of IL1A were 289 
repressed in both cell populations (Fig. 4b), suggesting that NOTCH signalling 290 
was transmitted from N1ICD-expressing cells to neighbouring cells. Among 291 
the five canonical NOTCH ligands12, we found a strong, unique upregulation 292 
of JAG1 upon ectopic N1ICD expression (Fig. 5a, Supplementary Fig. 5A). 293 
Although shedding of extracellular domain of JAG1 has been reported, we did 294 
not detect this in conditioned media (CM) from NIS cells (Supplementary Fig. 295 
5B)27. Induction of JAG1 was also observed during the transition to RIS with 296 
up and subsequent down-regulation mirroring the dynamic expression of 297 
N1ICD (Supplementary Fig. 2A). Induction of senescence with increased 298 
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JAG1 was confirmed in N1ICD-expressing hTERT-RPE1 cells 299 
(Supplementary Fig. 5C). These results suggest that N1ICD activation 300 
induces a cell-contact dependent growth arrest through a process similar to 301 
embryonic lateral induction. To further corroborate this, we examined how 302 
downstream inhibition of NOTCH signalling in the mRFP-expressing target 303 
cells affected non-cell-autonomous suppression of proliferation in the co-304 
culture system. Consistent with our hypothesis, use of DAPT led to a dose-305 
dependent inhibition of the non-cell-autonomous growth arrest of mRFP-306 
expressing cells co-cultured with N1ICD-expressing cells (Fig. 5b, 307 
Supplementary Fig. 5D). As expected, it had no effect upon autonomous cell 308 
growth in cells expressing N1ICD, which acts downstream of gamma 309 
secretase activity (Fig. 5c). More specifically, dnMAML1-mediated inhibition of 310 
NOTCH signalling only in the mRFP-expressing target cells also led to 311 
resistance to the non-cell-autonomous growth arrest in the co-culture system 312 
(Fig. 5d).  313 
 314 
We next inhibited NOTCH ligand activity in N1ICD-expressing cells. RNAi-315 
mediated knockdown of JAG1 in the N1ICD-expressing IMR90 cells had no 316 
effect upon cell autonomous growth of these cells (Fig. 5e, f), but led to a 317 
dose-dependent inhibition of the non-cell-autonomous growth arrest in the co-318 
cultured mRFP-expressing cells (Fig. 5g, Supplementary Fig. 5D). Culturing 319 
the N1ICD- and mRFP-expressing cells apart using a transwell chamber led 320 
to only a marginal decrease in proliferation of the mRFP-labelled cells (Fig. 321 
5h), supporting the critical role for cell-cell contact in activation of NOTCH 322 
signalling and subsequent senescence induction in cells adjacent to N1ICD-323 
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expressing cells. Similar NOTCH-mediated senescence transmission was 324 
also observed in mRFP-expressing IMR90 cells co-cultured with N1ICD-325 
expressing RPE1 cells, where JAG1 was upregulated (Supplementary Fig. 326 
5C, E). Although it is known that TGF-β signalling can induce JAG1 327 
expression28, neither TGFBR1 inhibitors or expression of dnSMAD4 affected 328 
the N1ICD-mediated upregulation of JAG1 in HDFs (Fig. 5i), reinforcing that 329 
NOTCH is an upstream regulator of TGF-β. Together, these data indicate that 330 
N1ICD-expression leads to cell-autonomous upregulation of both JAG1 and 331 
TGF-β ligands; the former triggers lateral induction of NOTCH signalling, and 332 
together with TGF-β signalling, induces senescence in neighbouring cells 333 
(Supplementary Fig. 5F). Interestingly, the NOTCH-mediated transmission of 334 
senescence was blocked by co-existing RIS cells, which were expressing 335 
dnMAML1 to minimise the inhibitory effect of NOTCH on the ‘RIS-secretome’, 336 
highlighting the functional distinction between non-autonomous activities of 337 
the two phases of RIS. This might also be involved in the negative feedback 338 
of NOTCH activity observed in the late phase of RIS in culture 339 
(Supplementary Fig. 5G). 340 
 341 
NOTCH1 activation during OIS in vivo 342 
To test whether Notch signalling is involved in senescence in vivo, we first 343 
examined KrasG12D-driven pancreatic intraepithelial neoplasia (PanIN) in 344 
KrasLSL-G12D; p48-cre mice, previously demonstrated to show evidence of 345 
senescence29. It was shown that Hes1 is upregulated in KrasG12D-driven 346 
mouse PanIN30-32. While most cells in adult wild-type pancreas exhibited low 347 
levels of Notch1 (Supplementary Fig. 6A), Notch1 was highly upregulated in 348 
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PanIN cells that were positive for the senescence marker, Dec129, although 349 
the nuclear staining of Notch1 appeared heterogeneous (Supplementary Fig. 350 
6A). Notch1 was also upregulated in acinar to ductal metaplasia, a potential 351 
histological precursor for PanIN, previously linked to senescence33 352 
(Supplementary Fig. 6A).  353 
 354 
Non-cell-autonomous effects of NOTCH1 on immune clearance of 355 
senescent cells 356 
We also examined the level of Notch1 in a mouse liver OIS model, in which 357 
transposable elements containing oncogenic NRASG12V are stably transduced 358 
to hepatocytes through the hydrodynamic tail-vein injection (HDTV): it was 359 
shown that NRASG12V-driven senescent hepatocytes are often surrounded by 360 
immune cells, and progressively cleared by a CD4+ T-cell-dependent immune 361 
reaction8. We found that cellular levels of Notch1 were upregulated in 362 
hepatocytes expressing NRASG12V, but not in hepatocytes expressing the 363 
non-functional NRASG12V/D38A (Fig. 6a).  364 
 365 
To test whether Notch inhibition during NRASG12V-driven hepatocyte 366 
senescence would modulate immune-mediated clearance of these cells, we 367 
compared two cohorts of mice, injected with NRASG12V or NRASG12V 368 
combined with dnMAML1. Consistent with previous reports8, we observed a 369 
time-dependent clearance of NRASG12V-induced senescent hepatocytes (Fig. 370 
6b, c). In the presence of Notch inhibition, this clearance was accelerated with 371 
a reduction in NRASG12V- and p21-expressing hepatocytes at d12 post-HDTV 372 
(Fig. 6b, c). Strikingly, in NRASG12V-expressing hepatocytes, the frequency of 373 
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nuclear Hes1 positive cells progressively increased over time (Fig. 6d, 374 
Supplementary Fig. 6B), while, at d12 when most NRASG12V-expressing 375 
hepatocytes had been eliminated, the frequency was more variable between 376 
mice. Thus, the dynamic regulation of Notch activity observed in vitro 377 
OIS/DDIS (Fig. 2b, c) was recapitulated in vivo. Moreover, NRAS-expressing 378 
hepatocytes were often associated with neighbouring Hes1- or p21-379 
expressing hepatocytes that did not express NRAS, at least at d9 (Fig. 6d, 380 
Supplementary Fig. 6C, D), providing in vivo evidence for senescence-381 
associated lateral induction of Notch signalling. Note, we failed to observe any 382 
inhibition of NRASG12V-driven senescence (probed by p21) by dnMAML1, 383 
particularly up to d9, in both NRAS-positive and negative hepatocytes (Fig. 384 
6c, Supplementary Fig. 6E): we speculate that dnMAML1 is likely to inhibit 385 
juxtacrine-mediated, but not paracrine-mediated4-6 or cell-autonomous, 386 
senescence. These data reinforce the immune-modulating function of Notch 387 
expression. 388 
 389 
We confirmed the recruitment of immune cells into the liver injected with 390 
NRASG12V; recruitment of CD3+ T-lymphocytes, but not B220+ B-391 
lymphocytes, was significantly accelerated in NRASG12V-IRES-dnMAML1 392 
injected livers compared to NRASG12V-IRES-mVenus injected animals (Fig. 393 
6c, Supplementary Fig. 6F and G).  394 
 395 
Leucocyte recruitment to the liver requires a leucocyte adhesion cascade to 396 
sinusoidal endothelial cells, which separate the liver parenchyma from 397 
sinusoidal blood flow34. To examine the effect of NOTCH1-modulated 398 
 17
secretomes upon lymphocyte recruitment, we performed an in vitro flow 399 
adhesion assay35: Human sinusoidal endothelial cells (HSECs), derived from 400 
explanted livers, were incubated in differentially conditioned media (CM) from 401 
IMR90 cells, prior to analysis of the ability of peripheral blood lymphocytes 402 
(PBLs) from healthy volunteers to adhere to HSECs under conditions of shear 403 
stress, recapitulating the physiological context of liver sinusoids 404 
(Supplementary Fig. 7A, B). CM from late phase (d6) of RIS IMR90 cells led 405 
to a significant increase in PBL adherence to HSECs and this effect was 406 
abrogated by co-expression of N1ICD (Fig. 6e). Similarly, inhibition of the 407 
NOTCH-regulated secretome at RIS transition (d3) led to significant increases 408 
in PBL adherence to HSEC when compared to HRASG12V-conditioned 409 
medium (Fig. 6e). Therefore, RIS-driven secreted factor(s) act upon HSECs to 410 
facilitate lymphocyte adhesion, which is negatively regulated by NOTCH 411 
through modulation of the SASP.  412 
 413 
We next injected NRASG12V or NRASG12V-IRES-N1ICD into mice; surprisingly, 414 
the number of NRAS-positive hepatocytes was much lower in the presence of 415 
ectopic N1ICD even at d6 (Fig. 7a). To understand potential reasons for this, 416 
we stained the livers for cleaved Caspase 3 (CC3), an apoptosis marker, and 417 
found hepatocytes expressing NRASG12V-IRES-N1ICD were often CC3-418 
positive (Fig. 7b, c). Nevertheless, in longer-term cohorts, most NRASG12V-419 
IRES-N1ICD-, but no NRASG12V-,injected mice developed liver tumours (Fig. 420 
7d, e, f). Thus, despite the efficient induction of apoptosis, ectopic NRASG12V 421 
and N1ICD cooperate to drive tumorigenesis. It remains to be elucidated 422 
whether this tumour formation is due to escape from senescence arrest 423 
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and/or senescence surveillance, but the results underscore the context-424 
dependent interaction between RAS and NOTCH signalling during 425 
tumorigenesis.  426 
 427 
Our data collectively suggest that, at the endogenous level, Notch signalling 428 
modulates SASP composition in senescent hepatocytes, controlling the 429 
immune reaction in the liver and thereby negatively regulating the elimination 430 
of senescent hepatocytes, at least in part through suppressing T-lymphocyte 431 
recruitment to the liver. 432 
 433 
NOTCH1 regulates senescence secretome through repression of 434 
C/EBPβ 435 
To examine how NOTCH1 controls secretome composition, we measured the 436 
impact of N1ICD on two TFs: NFκB and C/EBPβ, previously shown to 437 
cooperatively regulate the SASP6,21,36. NFκB activation is primarily regulated 438 
through nuclear translocation, and consistent with previous studies20,36, the 439 
level of chromatin-bound RELA/p65, the major component of NFB, was 440 
increased in RIS cells with its level in whole cell lysates being unchanged 441 
(Fig. 8a). In distinction, C/EBPβ was upregulated in both whole cell and 442 
chromatin fractions during RIS (Fig. 8a)6,21,36. Strikingly, ectopic N1ICD 443 
expression diminished levels of C/EBPβ, but not RELA, in both whole and 444 
chromatin fractions in RIS cells (Fig. 8a, compare lanes 2 and 4), although 445 
ectopic N1ICD appeared to be sufficient to inhibit the basal level of chromatin-446 
bound RELA (Fig. 8a, compare lanes 1 and 3, Supplementary Fig. 8A). 447 
 448 
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In addition, N1ICD-mediated repression of C/EBPβ was abrogated in the 449 
presence of dnMAML1 (Fig. 8b). GSEA revealed enrichment of a C/EBPβ-450 
signature37 in NIS or N+RIS-downregulated genes, and RIS-upregulated 451 
genes (Supplementary Fig. 8B), suggesting that the transcriptional activity of 452 
C/EBPβ is broadly diminished in N1ICD-expressing IMR90 cells. 453 
 454 
CEBPB translates from different in-frame start sites generating two 455 
transcriptional activators, LAP* and LAP (Liver-activating protein), and an N-456 
terminally truncated transcriptional inhibitor, LIP (Liver inhibitory protein)6. We 457 
introduced full length CEBPB cDNA (LAP*, see METHODS) 6, to inducible 458 
N1ICD-expressing IMR90 cells. The enforced expression of LAP* in N1ICD-459 
expressing cells fully restored expression of IL-8 (Fig. 8c, compare lanes 2 460 
and 4) and IL1A (Fig. 8d), suggesting that repression of pro-inflammatory 461 
cytokines by N1ICD is primarily mediated by inhibition of C/EBPβ, although 462 
we do not exclude a role for N1ICD in qualitative regulation of the NFB 463 
pathway.  464 
 465 
The preferential downregulation of C/EBPβ was also observed when IMR90 466 
cells were treated with recombinant TNF-α. Ectopic N1ICD, which inhibited 467 
TNF-α-mediated pro-inflammatory cytokine induction, had no effect on the 468 
level of TNF-α-activated RELA (Fig. 8e) or other NFB family components 469 
(Supplementary Fig. 8C), whereas N1ICD efficiently downregulated C/EBPβ 470 
in both basal and TNF-α-treated conditions. Further, ectopic N1ICD-driven 471 
downregulation of C/EBPβ was also observed in the HaCaT cells, where 472 
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N1ICD failed to induce senescence, suggesting that NOTCH1-mediated 473 
C/EBPβ inhibition is not limited to senescence (Supplementary Fig. 8D). 474 
 475 
It is well established that IL-1α acutely activates NFκB and C/EBPβ to induce 476 
their targets, including IL1B, IL6, and IL838. In the context of senescence, it 477 
was shown that IL-1α is an upstream SASP effector, regulating a cytokine 478 
network through NFκB and C/EBPβ21. Thus, it is possible that N1ICD 479 
negatively regulates IL-1α and thereby C/EBPβ. However, overexpression of 480 
C/EBPβ was sufficient for inducing IL1A even in the presence of ectopic 481 
N1ICD (Fig. 8d). In addition, when we treated N1ICD-expressing cells with 482 
recombinant IL-1α, we observed only a modest increase of C/EBPβlevels, 483 
whereas IL-6 was strongly upregulated to a level higher than control cells (Fig. 484 
8f), suggesting that IL-1α, like IL-1β/6/8, is also downstream of C/EBPβ.  485 
 486 
Unlike IL1B/6/8, the transcriptional regulation of IL1A is unclear. To test 487 
whether C/EBPβ directly regulates IL1A expression during senescence, we 488 
first characterised the basal profile of C/EBPβ binding sites along with key 489 
epigenetic marks in IMR90 cells using external datasets39,40. We found 490 
several C/EBPβ peaks around the IL1A locus, including a modest ‘proximal’ 491 
C/EBPβ peak at the transcriptional start site (TSS) and a prominent ‘distal’ 492 
site ~8kb upstream of the TSS (Supplementary Fig. 8E). The proximal and 493 
distal sites were enriched for promoter and enhancer markers, respectively 494 
(Supplementary Fig. 8E). Interestingly, these two sites were recently identified 495 
as a promoter-enhancer pair, forming a looping interaction41, suggesting that 496 
this distal site is an enhancer for IL1A. Next, we performed C/EBPβ ChIP-497 
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qPCR, targeting these two regulatory regions of IL1A, as well as known 498 
C/EBPβ binding sites at the IL6/8 loci in IMR90 cells expressing N1ICD, 499 
HRASG12V, or both. Consistent with previous reports6, C/EBPβ promoter 500 
binding at the IL6/8 loci was increased in RIS cells (Supplementary Fig. 8F). 501 
Similarly, we found that C/EBPβ binding at promoter and, more prominently, 502 
enhancer regions of IL1A was also increased (Fig. 8g), reinforcing that IL1A is 503 
a direct C/EBPβ target. In addition, co-expression of N1ICD resulted in 504 
reduced enrichment of C/EBPβ at these regulatory regions in the context of 505 
HRASG12V (Fig. 8g). We propose that NOTCH1 inhibits pro-inflammatory 506 
cytokines, including IL-1α, primarily through repression of their C/EBPβ-507 
mediated transcription (Fig. 8h). 508 
 509 
DISCUSSION 510 
The data that we present here suggests that the SASP is not a singular entity, 511 
but a complex evolving entity with tightly regulated composition and spatial 512 
activity, dependent upon levels of NOTCH activity. We provide evidence for 513 
an additional layer of non-autonomous activity of senescence: ‘lateral 514 
induction’, which was originally described in NOTCH-mediated control of 515 
boundary formation during embryonic development25. Interestingly, recent 516 
studies have identified embryonic senescence as a mechanism for 517 
developmental patterning: these senescent cells are accompanied by 518 
upregulation of TGF-β signalling and subsequent immune-clearance 42,43.  519 
 520 
Another TF involved in embryonic development, GATA4, positively regulates 521 
the SASP in part through upregulation of IL-1α44 and NOTCH signalling 522 
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appears to have a negative impact on GATA4 45. It would also be interesting 523 
to test whether GATA4 plays a role in NOTCH-mediated inhibition of the 524 
C/EBPβ-IL1a axis. Additional implications of our data include a possibility that 525 
constitutively active NOTCH signalling in tumour cells drive lateral induction of 526 
senescence in the stroma. Emerging evidence suggests the important role of 527 
bone marrow stroma in survival/maintenance of T-cell ALL, which is 528 
associated with activating mutations of NOTCH146. It would be important to 529 
test whether NOTCH signalling derived from T-ALL cells can induce NIS-like 530 
phenotype in the bone marrow stromal cells, which might have a substantial 531 
impact on the T-ALL niche.  532 
 533 
Finally, therapeutic elimination of senescent cells has been suggested to 534 
provide beneficial effects on tissue homeostasis or tumour suppression7,8,47,48. 535 
Manipulation of NOTCH may provide a unique therapeutic opportunity for 536 
targeting senescent cells through modulation of senescence surveillance.  537 
 538 
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FIGURE LEGENDS 702 
Figure 1. Plasma membrane proteomics (PMP) defines NOTCH1 as 703 
upregulated in OIS. (a) The workflow for quantitative PMP using differential 704 
SILAC labelling of growing and HRASG12V-induced senescent (RIS) IMR90 705 
cells. (b) GO cellular compartment term enrichment for all 1502 identified 706 
proteins in both conditions. (c) Volcano plot of 521 high-confidence protein 707 
identifications from PMP demonstrating log2 fold change (RIS(d6) / Growing) 708 
against negative log10 p value (n = 4 independent experiments). Among 167 709 
proteins differentially expressed during RIS (p<0.05), red dots indicate 94 710 
proteins with more than two fold change. (d) Cell surface NOTCH1 expression 711 
by flow-cytometry in indicated IMR90 cells: left, ER:HRASG12V cells with (d6) 712 
or without (Growing) 4OHT, iso-IgG, isotype control IgG; centre, cells with 713 
constitutive overexpression of either HRASG12V, E1A, or both; right, DNA 714 
damage-induced senescence (DDIS). To establish DDIS, cells were treated 715 
with 100μM Etoposide for 2 days, followed by 5-days incubation in drug-free 716 
medium.  717 
 718 
Figure 2. Dynamic canonical NOTCH1 signalling is responsible for 719 
reciprocal regulation of TGF-β ligands and pro-inflammatory cytokines 720 
during senescence. (a) Time series analysis of cell surface NOTCH1 721 
expression during RIS in IMR90 cells by flow cytometry. Values are means 722 
relative to d0 ± SEM; n = 3. (b and c) Time course of protein expression by 723 
immunoblotting during RIS (b) or DDIS (c). (d) ER:HRASG12V IMR90 cells, 724 
expressing dnMAML1-mVenus or matched control, were incubated with or 725 
without 4OHT for 3 days and analysed for expression of indicated mRNA and 726 
 28
proteins by qRT-PCR and immunoblotting respectively; n ≥ 4; unpaired T-test. 727 
(e) ER:HRASG12V IMR90 cells, expressing a doxycycline-inducible N1ICD-728 
FLAG construct (TRE-N1ICD) were analysed after 6 days treatment with 729 
4OHT with or without doxycycline at indicated concentrations from d3 by qRT-730 
PCR and immunoblotting; n = 5; unpaired T-test. Values are mean ± SEM; *P 731 
≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. Statistics source data for a, d & e are 732 
provided in Supplementary Table 2. 733 
  734 
Figure 3. NOTCH1 drives a cell-autonomous senescence with a distinct 735 
secretory profile. (a and b) ER:HRASG12V IMR90 cells, stably expressing 736 
N1ICD-FLAG or control vector (V), were incubated with or without 4OHT for 6 737 
days and analysed for expression of indicated proteins by immunoblotting (a), 738 
SA-β-gal and BrdU incorporation (b). One way ANOVA with Dunnett's multiple 739 
comparison test; bars are means of ≥200 cells, n = 4. ***P ≤ 0.001 versus 740 
control cells. Scale bar 100μm. (c) Time series analysis of indicated 741 
transcripts after doxycycline (Doxy) induction in TRE-N1ICD-FLAG IMR90 742 
cells by qRT-PCR. Values are mean ± SEM, n = 3. Inset, immunoblotting of 743 
fractionated chromatin in IMR90 cells expressing HRASG12V (d6) or TRE-744 
N1ICD-FLAG (d3) for downstream TGF-β phosphorylation-target SMAD3 745 
(phos-SMAD3). (d) TRE-N1ICD-mVenus IMR90 cells with or without 3 days of 746 
doxycycline were analysed for cell surface expression of the TGFB1 gene 747 
product latency-associated peptide by flow cytometry. (e) Differentially 748 
expressed transcripts in N1ICD-, HRASG12V- or Etoposide-induced senescent 749 
IMR90 cells (NIS, RIS, or DDIS, respectively), compared to normal control 750 
cells. Heat map shows z-score normalised fold changes of 1150 secretome 751 
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genes differentially expressed in at least in one comparison. Representative 752 
KEGG pathways enriched in four clusters (False discovery rate (FDR) < 0.01) 753 
are shown. (f) TRE-N1ICD-FLAG IMR90 cells treated with or without 754 
doxycycline for 3 days with or without TGF-β receptor antagonists (#1, 755 
SB431542; #2, A83-01) were analysed by qRT-PCR and immunoblotting for 756 
the indicated mRNA and proteins in addition to proliferation and cell cycle 757 
analyses. Values are mean ± SEM, n ≥ 3. Statistics source data for b, c & f 758 
are provided in Supplementary Table 2. 759 
 760 
Figure 4. NOTCH1 drives non-cell-autonomous senescence partly 761 
dependent upon TGF-β. (a) The proliferative ability of mRFP cells was 762 
analysed during co-culture with unlabelled senescent cells by proliferation 763 
analysis; representative images demonstrating co-cultured cells. Scale bar 764 
150 μm. NIS, doxycycline was added at d0 to induce N1ICD; RIS, 765 
ER:HRASG12V was pre-induced for 4 days before co-culture; DDIS, 766 
senescence was induced by etoposide as in Figure 2C for 4 days before co-767 
culture. (b) mRFP cells were co-cultured with doxycycline-inducible TRE-768 
N1ICD cells treated with or without doxycycline for 3 days prior to flow sorting 769 
and expression analysis of the 2 cell populations for the indicated transcripts 770 
by qRT-PCR; unpaired T-test; bars are means, n = 3. (c) The proliferative 771 
ability of mRFP IMR90 cells was analysed during co-culture with TRE-N1ICD 772 
IMR90 cells treated with or without doxycycline and TGF-β receptor 773 
antagonists; representative result from n = 5. (d and e) mRFP (puromycin-774 
resistant) cells were co-cultured with cells stably expressing N1ICD-FLAG 775 
(hygromycin-resistant) for 7 days prior to puromycin selection to selectively 776 
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remove N1ICD-expressing cells, yielding populations that were ~99% mRFP-777 
positive by flow cytometry. mRFP cells were then analysed for expression of 778 
indicated proteins by immunoblotting (d), SA-β-gal and DNA synthesis by 779 
BrdU incorporation (e); unpaired T-test; values are mean ± SEM of ≥200 cells 780 
from 8 high power fields, n = 7. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. Scale bar 781 
200 μm. Statistics source data for b & e are provided in Supplementary Table 782 
2. 783 
 784 
Figure 5. NOTCH1 drives juxtacrine senescence through JAG1-mediated 785 
lateral induction in IMR90 cells. (a) Time series analysis of JAG1 786 
expression by immunoblotting (upper) and at the cell surface by flow 787 
cytometry (lower) after doxycycline induction in TRE-N1ICD cells. (b) The 788 
proliferative ability of mRFP cells was analysed during co-culture with TRE-789 
N1ICD cells treated with or without doxycycline and the gamma secretase 790 
inhibitor DAPT at indicated concentrations; representative result from n = 4. 791 
(c) The proliferative ability of TRE-N1ICD cells was analysed with or without 792 
doxycycline and DAPT at indicated concentrations; representative result from 793 
n = 4. (d) The proliferative ability of mRFP cells with stable expression of 794 
dnMAML1-mVenus or mVenus alone was analysed during co-culture with 795 
TRE-N1ICD cells treated with or without doxycycline; representative result 796 
from n = 4. (e and f) Expression of JAG1 and proliferation of TRE-N1ICD cells 797 
stably expressing vector or indicated shRNAs targeting JAG1, demonstrated 798 
by immunoblot (e) and proliferation analysis with or without doxycycline (f); 799 
representative result from n = 4. (g) The proliferative ability of mRFP cells was 800 
analysed during co-culture with TRE-N1ICD cells with or without sh-JAG1 and 801 
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with or without doxycycline. (h) mRFP cells were analysed for BrdU 802 
incorporation, when physically separated from TRE-N1ICD cells treated with 803 
or without doxycycline in a transwell chamber; unpaired T-test; ≥200 cells 804 
from 8 high power fields; n = 5. (i) TRE-N1ICD cells treated with or without 805 
doxycycline and TGF-β receptor antagonists (left) or co-transfected with 806 
vector or dnSMAD4 (right) were analysed for JAG1 expression by qRT-PCR; 807 
n = 3; 1, SB431542; 2, A83-01. One way ANOVA with Dunnett's multiple 808 
comparison test (left) or unpaired t-test (right); bars are means (h and i) ± 809 
SEM (h). Statistics source data for h & i are provided in Supplementary Table 810 
2. 811 
 812 
Figure 6. NOTCH1 is dynamically upregulated within NRAS-senescent 813 
hepatocytes and inhibits senescence surveillance. (a) Livers were 814 
harvested from mice 12 days after hydrodynamic tail vein injection of 815 
NRASG12V or inactive NRASG12V/D38A-bearing transposons and analysed by 816 
immunohistochemistry for NRAS and Notch1 expression in serial sections; 817 
Quantification of NRAS+ hepatocytes expressing NOTCH1; values are mean 818 
± SEM from manual counting of ≥200 cells; n = 3 mice per condition. Insets, 819 
magnified pictures of dotted rectangular areas. Scale bar 200 μm. (b) Time 820 
series analysis of hepatic NRAS-expression by immunohistochemistry after 821 
injection of NRASG12V(-IRES-mVenus) or NRASG12V-IRES-dnMAML1(-822 
mVenus). Scale bar 200 μm. (c) Quantification of NRAS, p21, or CD3 (T-823 
lymphocyte marker) positive cells within livers of mice treated as in (b); 824 
unpaired T-test; values are mean ± SEM from manual counting (NRAS) or 825 
automated image analysis of ≥105 cells (p21 / CD3) from liver sections (see 826 
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METHODS); n ≥ 3 mice per condition; *P ≤ 0.05, **P ≤ 0.01. (d) Lateral 827 
induction of Notch signalling in mouse livers treated as in (b). Representative 828 
immunohistochemistry of NRAS and Hes1 at d9 in serial sections. Insets, 829 
magnified pictures of dotted rectangle areas. Asterisk demonstrates Hes1-830 
expressing, NRAS-negative cells adjacent to NRAS-expressing hepatocytes. 831 
Arrowheads demonstrate positive internal control staining of Hes1 within 832 
cholangiocytes. The percentage of NRAS-positive cells with adjacent Hes1-833 
positive (but not NRAS) were manually counted; n = 3 mice per condition; 834 
bars are means; unpaired T-test. Similar results were also obtained using dual 835 
staining in the same section (Supplemental Fig. 6C). Scale bar 200 μm. (e) 836 
Flow-based assay of peripheral blood lymphocyte (PBL) adherence 837 
(cells/mm2/106) to human liver sinusoidal endothelial cells (HSEC) from 3 838 
separate individuals pre-incubated with conditioned media (CM) from IMR90 839 
cells expressing ER:HRASG12V and TRE-N1ICD with or without 4OHT (d6) 840 
and/or doxycycline (d3)  (left; n = 3); or CM from ER:HRASG12V IMR90 cells, 841 
expressing dnMAML1-mVenus or matched control and incubated with or 842 
without 4OHT for 3 days (right; n = 3) (see Supplementary Fig. 7A, B). 843 
Representative images (bottom) demonstrating adherent PBLs (arrows) to 844 
HSEC after pre-incubation with indicated CM. One way ANOVA with 845 
Dunnett's multiple comparison test; bars are mean; *P ≤ 0.05, **P ≤ 0.01. 846 
Scale bar 50μm. Statistics source data for a, c, d & e are provided in 847 
Supplementary Table 2. 848 
 849 
Figure 7. Co-expression of NRASG12V and N1ICD drives short-term 850 
apoptosis and long-term tumourigenesis in the liver. (a-c) Livers from 851 
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mice injected with either NRASG12V (n = 10) or NRASG12V-IRES-N1ICD (n = 852 
11) were subjected to IHC for NRAS and cleaved caspase 3 staining at the 853 
indicated time points in serial sections. Relatively fewer NRAS-positive 854 
hepatocytes were detected in the NRASG12V-IRES-N1ICD cohort (d6 (n = 4) 855 
and d12 (n = 7)) (a), and these NRAS-positive cells were mostly positive for 856 
cleaved caspase 3 (d6) (b, c). Insets are magnified pictures of dotted 857 
rectangular areas (b). Bars are means from automated image analysis of ≥105 858 
cells from each liver section; n ≥ 4 mice per condition; unpaired t-test. Scale 859 
bar 200 μm. (d) Mice injected with NRASG12V (n = 7) or NRASG12V-IRES-860 
N1ICD (n = 9) underwent long-term follow-up; necropsy was performed in all 861 
to confirm the presence of liver tumours. Kaplan-Meier plots of cancer-free 862 
survival from the 2 cohorts; survival analysis by Log-rank test. (e) Example 863 
images of gross liver pathology at 2 months post-HDTV injection of one 864 
mouse from each cohort revealing a large tumour (long black arrow) and 865 
multiple small cystic lesions in the liver injected with NRASG12V-IRES-N1ICD. 866 
(f - g) Immunohistochemical and H&E staining of serial liver sections from 867 
each cohort for the indicated proteins. H&E staining demonstrating tumour (T) 868 
infiltrating the surrounding normal parenchyma (N) and strong tumoural 869 
immunohistochemical staining for the proliferative marker ki67 in serial 870 
sections (g). Images in (g) are magnified views of dotted rectangular areas in 871 
(f).  *P ≤ 0.05, **P ≤ 0.01. Scale bar upper panels 5mm, lower panels 200 μm. 872 
Statistics source data for a & c are provided in Supplementary Table 2. 873 
 874 
Figure 8. NOTCH1 controls the pro-inflammatory SASP through 875 
repression of C/EBPβ. (a) ER:HRASG12V/TRE-N1ICD-FLAG IMR90 cells 876 
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treated with or without 6 days of 4OHT and 3 days of doxycycline were 877 
analysed for expression of RELA and C/EBPβ in whole cell lysate and 878 
fractionated chromatin by immunoblotting. (b) Time series analysis of 879 
chromatin-bound N1ICD-FLAG and C/EBPβ after doxycycline treatment of 880 
TRE-N1ICD IMR90 cells with or without dnMAML1. (c and d) TRE-N1ICD 881 
IMR90 cells with or without ectopic C/EBPβ-LAP* and 3 days of doxycycline 882 
treatment were analysed for C/EBPβ, IL-8 (c) and IL1A (d) expression by 883 
immunoblot and qRT-PCR; n = 3. (e) TRE-N1ICD IMR90 cells treated with or 884 
without doxycycline for 3 days, then with or without 100ng/ml TNF-α for 1 hour 885 
were analysed for expression and chromatin binding of indicated mRNA and 886 
proteins by qRT-PCR and immunoblot respectively; unpaired T-test; n = 3; 887 
bars are means. (f) TRE-N1ICD IMR90 cells treated with or without 888 
doxycycline for 3 days, and 10ng/ml IL-1α for the final 24 hours were 889 
analysed by immunoblotting. (g) ER:HRASG12V- and TRE-N1ICD-FLAG-890 
expressing IMR90 cells treated with or without 6 days of 4OHT and 3 days of 891 
doxycycline were subjected to chromatin immunoprecipitation of endogenous 892 
C/EBPβ and subsequent qPCR for proximal and distal sites at the IL1A locus 893 
(Supplemental Figure 8E and METHODS); n = 3; One way ANOVA with 894 
Dunnett's multiple comparison test; values are mean ± SEM. (h) Model for 895 
NOTCH-mediated SASP switch during senescence. *P ≤ 0.05, **P ≤ 0.01, 896 
***P ≤ 0.001.  Statistics source data for d, e & g are provided in 897 
Supplementary Table 2. 898 
 899 
 900 
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METHODS 1 
Cell culture 2 
IMR90 (ATCC), WI38 (ATCC) and ESFs (embryonic skin fibroblasts)49 (a kind 3 
gift from Dr. Jesus Gil, Imperial College, London) human diploid fibroblasts 4 
were cultured as previously described in DMEM /10% fetal calf serum (FCS) 5 
in a 5% O2 / 5% CO2 atmosphere. hTERT-RPE1 cells (a telomerase-6 
immortalised human retinal pigment epithelial cell line) (ATCC) were grown in 7 
DMEM/F12 / 10% FCS in a 5% O2 / 5% CO2 atmosphere. HACAT, cells 8 
(ATCC) were cultured in DMEM / 10% FCS in a 21% O2  / 5% CO2 9 
atmosphere.  No cell lines used in this study were found in the database of 10 
commonly misidentified cell lines that is maintained by ICLAC and NCBI 11 
Biosample. Cell identity was confirmed through STR genotyping. Regular 12 
testing was always negative for mycoplasma contamination. 13 
 14 
The following drugs and inhibitors were used: 4-hydroxytamoxifen (4OHT) 15 
(Sigma); N-[(3,5-Difluorophenyl)acetyl]-L-alanyl-2-phenyl]glycine-1,1-16 
dimethylethyl ester (DAPT) (Sigma); SB431542 (Tocris); A 83-01 (Tocris); 17 
GW788388 (Tocris); Etoposide (Sigma); recombinant human TGF-β1 (Cell 18 
Signaling); recombinant human TGF-β2 (Peprotech); recombinant human 19 
TGF-β3 (Peprotech); Tumor necrosis factor alpha (TNF-α); recombinant IL-1α 20 
(both R&D systems). 21 
 22 
Vectors 23 
The following retroviral vectors were used in this study: pBabe-puro for 24 
HRASG12V50, C/EBPβ-LAP* (alternative start codons were replaced with TTG; 25 
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a kind gift from Dr. Daniel Peeper, NKI, Amsterdam)6; pLNCX2 (Clontech) for 26 
ER:HRASG12V15; pLNCX (Clontech) for ∆MEK1:ER (∆N3, S218E, S222D)51; 27 
pWZL-hygro for N1ICD-FLAG (residues 1758 – 2556 of human NOTCH1, as 28 
described52), mRFP1; pLPC-puro for dnMAML1-mVenus (residues 12 – 74 of 29 
human MAML1), N1ICD-FLAG, mRFP1; pQCXIH-i N1ICD-FLAG, N1ICD-30 
FLAG-mVenus, C/EBPβ-LAP*, dnSMAD4-mVenus (residues 1 - 514 of 31 
human SMAD4, as described 24); pQCXIN-i for N1ICD-FLAG; pMSCV-miR30-32 
puro for shJAG1 (target sequences: #1, 5’-GCGTGACCTGTGATGACTACT-33 
3’; and #4, 5’-GGTCTTTGAGCTCCCACTTCT-3’).  34 
 35 
The tetracycline-inducible retroviral vectors (pQCXIH-i and pQCXIN-i) were 36 
cloned using the following strategies. A third generation tet-responsible 37 
element (TRE3G) and a constitutively expressed rtTA3 tet-transactivator 38 
cassette were PCR-amplified from pCLIIP-i19. These two fragments were 39 
assembled by overlap-extension PCR and the product was cloned into 40 
pQCXIH or pQCXIN (Clontech). 41 
 42 
Plasmids for Hydrodynamic tail-vein injection: pPGK-SB13, pT/CAGGS for 43 
NRASG12V, NRASG12V/D38A8, NRASG12V-IRES-mVenus, NRASG12V-IRES-44 
dnMAML1-mVenus, NRASG12V-IRES-N1ICD-FLAG).  45 
SILAC labelling 46 
Cells were cultured in SILAC DMEM (Thermo) supplemented with 10% 47 
dialysed FCS (Life Technologies), L-proline (280mg/l, Sigma), L-glutamine 48 
(Life technologies) and either light (Arg 0, Lys 0) (Sigma), medium (Arg 6, Lys 49 
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4) or heavy (Arg 10 Lys 8) amino acids (CKGas) at 150mg/l and 85mg/l for 50 
lysine and arginine respectively. Cells were cultured for 9 days to allow 51 
complete labelling of the proteome with the appropriate amino acids before 52 
induction of senescence. 53 
 54 
Plasma membrane proteomics 55 
PMP was performed as described previously14. Briefly, surface sialic acid 56 
residues were oxidised, biotinylated with aminooxy-biotin (Biotium), and 57 
biotinylated cells incubated in a 1% Triton X-100 lysis buffer. Biotinylated 58 
glycoproteins were enriched with high affinity streptavidin agarose beads 59 
(Pierce) and washed extensively. Captured protein was reduced and alkylated 60 
then digested with trypsin on-bead overnight. Tryptic peptides were collected 61 
and fractionated. Glycopeptides were eluted using PNGase (New England 62 
Biolabs). 63 
 64 
High pH reverse-phase high pressure liquid chromatography (HpRP-HPLC) 65 
was performed on tryptic peptides as described previously14. LC-MSMS was 66 
performed using a NanoAcquity uPLC (Waters, MA, USA) coupled to an LTQ-67 
OrbiTrap XL (Thermo, FL, UA). Raw MS files were processed using 68 
MaxQuant version 1.3.0.553. Reversed decoy databases were used and the 69 
false discovery rate for both peptides and proteins were set at 0.01. Protein 70 
quantitation utilised razor and unique peptides and required a minimum of 2 71 
ratio counts, with normalised protein ratios reported. Significance B values 72 
were calculated. We assessed the number of PM proteins identified as 73 
described previously14. 74 
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 75 
Proteomic Analysis 76 
Proteins were selected for differential expression analysis such that they had 77 
been quantified in at least two replicates, and that at least one of these 78 
quantifications was based on more than one peptide. A single sample t-test 79 
was then applied to the mean log2 fold change values to assess whether 80 
these were significantly different to zero. Proteins were selected as 81 
significantly differentially expressed if p value <0.05. All detected proteins 82 
were used for enrichment testing of GO localisation (Cellular Component) 83 
terms using Metacore (Thomson Reuters). ’High confidence’ was defined as 84 
follows: peptides identified in at least 2 independent replicates with at least 1 85 
replicate having 2 or more peptides. 86 
 87 
Expression profiling by mRNA sequencing 88 
RNA was extracted using the Qiagen RNeasy plus kit according to 89 
manufacturer’s instructions and RNA quality checked using a Bioanalyser 90 
Eukaryote Total RNA Nano Series II chip (Agilent). mRNASeq libraries were 91 
prepared from at least 6 biological replicates of each condition using the 92 
TruSeq Stranded mRNA Library Prep Kit (Illumina) according to the 93 
manufacturers instructions. Single-end 40bp reads generated on the Illumina 94 
HiSeq were aligned to the human genome version GRCh37.64 using TopHat 95 
v2.0.454. Read counts were then obtained using HTSeq-count v0.5.3p9 96 
(http://www-huber.embl.de/users/anders/HTSeq/doc/overview.html), 97 
normalised and tested for differential gene expression using the Bioconductor 98 
package DESeq v1.10.155. Multiple testing correction was applied using the 99 
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Benjamini-Hochberg method. Genes were selected as differentially expressed 100 
with a false discovery rate (FDR) of <0.01. Secretome genes were defined as 101 
previously described56. 102 
 103 
Network analysis of proteomic and transcriptomic data 104 
RIS-associated PMP data complemented by mRNA-Seq expression data 105 
were used to identify key senescence-associated membrane protein network 106 
hubs. Proteins detected through PMP were merged with genes, but genes 107 
annotated in the cellular membrane compartment were excluded. Log2 fold 108 
ratios were used for both proteomics and transcriptomic data. Data were 109 
analysed using Ingenuity Pathway Analysis (IPA) (QIAGEN); the possible 110 
interaction networks were generated using Ingenuity knowledge base 111 
and included only direct relationships. Default settings were used, apart from 112 
restricting the networks to experimentally observed interactions in human 113 
data. The highest scoring network as assigned by IPA, presented here, 114 
highlighted the importance of NOTCH1 as a key hub in the PMP data. For 115 
graph readability we removed interactions from non-hub genes. 116 
 117 
Chromatin isolation 118 
Chromatin isolation was performed as described previously50. 119 
 120 
BrdU incorporation, colony formation and SA-β-gal assays 121 
Cellular proliferation by BrdU incorporation, colony formation and SA-β-gal 122 
analysis have been described previously50.   123 
 124 
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Cellular proliferation by Incucyte 125 
Analysis of short-term cellular proliferation was performed in either an 126 
Incucyte-HD or Incucyte-Zoom device (Essen Bioscience) in a 21% O2 127 
atmosphere. Cells were plated, at 4 x 105 cells for monoculture or at 3.5 x 105 128 
signal-sending cells with 1.5 x 105 target cells, in a 12-well plate in 1ml cell 129 
culture media. Cell proliferation was determined through repeated measures 130 
of confluency on phase or epifluorescent imaging.   131 
Gene set enrichment analyses (GSEA) 132 
GSEA were performed as described57. P-values derived from DESeq 133 
analyses of the RNA-Seq data were –log10 transformed and then signed 134 
according to whether any particular genes was up(+)- or down(-)-regulated 135 
compared to control samples. These values were then used for ranking and 136 
weighting of genes in subsequent GSEA analyses58. Cell-cycle related 137 
genesets were obtained from the Molecular Signatures Database 138 
(http://software.broadinstitute.org/gsea/msigdb). Other gene signatures used 139 
were obtained from datasets in the Gene Expression Omnibus (GEO). 140 
 141 
Flow cytometry 142 
Cells were washed once with cold PBS, prior to dissociation with Versene 143 
(Life Technologies), washed twice more in PBS / 0.1% Fetal calf serum, 144 
blocked in 1% mouse or rabbit serum before incubation with combinations of 145 
the following fluorochrome-conjugated antibodies: anti-NOTCH1 146 
(Ebioscience, 17-9889, 1:50); anti-JAGGED1 (R&D systems, FAB1726A, 1:8); 147 
anti-latency associated peptide (Ebioscience, 17-9829, 1:20). Cells were then 148 
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washed twice more, before fixation with 4% PFA and analysis on a 149 
FACSCalibur (Becton Dickenson). Flow-based cell sorting was conducted on 150 
a FACSAria II cytometer (Becton Dickenson). Flow data was analysed with 151 
FlowJo v10. 152 
 153 
Laser Scanning Cytometry 154 
Cell cycle profile analysis was performed using Laser Scanning Cytometry on 155 
an iCys Research Imaging Cytometer (CompuCyte, Cambridge, MA) using 156 
anti-BrdU (BD, 555627, 1:500) and counter-staining with DAPI. 157 
 158 
mRNA expression by quantitative RT-PCR 159 
RNA was extracted using the Qiagen RNeasy plus kit as above and reverse 160 
transcribed to cDNA using the high capacity reverse transcription kit (Applied 161 
Biosystems). qRT-PCR was performed as described before50 with relative 162 
expression determined by the 2-∆∆Ct method59 using β-Actin (ACTB) as an 163 
internal control. Primer sequences are as follows:  164 
ACTB forward primer GGACTTCGAGCAAGAGATGG 165 
ACTB reverse primer AGGAAGGAAGGCTGGAAGAG 166 
CCNA2 forward primer GCGTTCACCATTCATGTGGA 167 
CCNA2 reverse primer CAGGGCATCTTCACGCTCTATT 168 
CDKN2B forward primer GCGTTCACTCCAATGTCTGCTG 169 
CDKN2B reverse primer TCCACTTTGTCCTCAGTCTTCAGG 170 
CEBPB forward primer CTTCAGCCCGTACCTGGAG 171 
CEBPB reverse primer GGAGAGGAAGTCGTGGTGC 172 
JAG1 forward primer TGGTCAACGGCGAGTCCTTTAC 173 
 8
JAG1 reverse primer GCAGTCATTGGTATTCTGAGCACAG 174 
TGFBI forward primer CCACCATCACCAACAACATCCAG 175 
TGFBI reverse primer GCCGTTACCTTCAAGCATCGTG 176 
IL1A forward primer AACCAGTGCTGCTGAAGGA  177 
IL1A reverse primer TTCTTAGTGCCGTGAGTTTCC  178 
IL1B forward primer CTGTCCTGCGTGTTGAAAGA  179 
IL1B reverse primer TTGGGTAATTTTTGGGATCTACA 180 
IL6 forward primer TGAAAGCAGCAAAGAGGCACTG  181 
IL6 reverse primer TGAATCCAGATTGGAAGCATCC 182 
IL8 forward primer AAGGAAAACTGGGTGCAGAG  183 
IL8 reverse primer: ATTGCATCTGGCAACCCTAC 184 
TGFB1 forward primer CAGAAATACAGCAACAATTCC 185 
TGFB1 reverse primer CTGAAGCAATAGTTGGTGTC 186 
TGFB3 forward primer TGCGTGAGTGGCTGTTGAGAAG 187 
TGFB3 reverse primer CCATTGGGCTGAAAGGTGTGAC 188 
HES1 forward primer ACGTGCGAGGGCGTTAATAC 189 
HES1 reverse primer ATTGATCTGGGTCATGCAGTTG 190 
HEY1 forward primer CCGCTGATAGGTTAGGTCTCATTTG 191 
HEY1 reverse primer TCTTTGTGTTGCTGGGGCTG 192 
 193 
Protein expression by immunoblotting and Immunofluorescence 194 
Immunofluorescence and immunoblotting, on SDS-PAGE on gels of various 195 
concentrations, were performed as described previously50. The following 196 
antibodies were used in this study: anti-HRAS (Calbiochem, OP-23, 1:500); 197 
Anti-Cyclin A2 (Sigma, C4710, 1:500); anti-NOTCH1 (Cell signaling, 4380, 198 
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1:1000); anti-N1ICD (Cell signaling, 4147, 1:500); anti-HES1 (Cell signaling, 199 
11988, 1:1000); anti-TGF-β1 (Cell signaling, 3709, 1:500); anti-IL-6 (R&D 200 
systems, MAB2061, 1:250); anti-IL-8 (R&D systems, MAB208, 1:500); anti-β-201 
Actin (Sigma, A5441, 1:5000); anti-GFP (Clontech, 632377, 1:1000); anti-Rb 202 
(Cell signaling, 9309, 1:1000); anti-JAGGED1 (Cell signaling, 2155, 1:1000); 203 
anti-FLAG (Cell signaling, 2368, 1:1000); anti-C/EBPβ-LAP (Cell signaling, 204 
3087, 1:1000); anti-C/EBPβ (Santa-Cruz, sc-150, 1:500); anti-Histone H3 205 
(Abcam, Ab-1791, 1:10,000); anti-RelA (Cell signaling, 3034, 1:1000); anti-206 
RelB (Cell signaling, 4922, 1:1000); anti-c-Rel (Cell signaling, 4727, 1:1000); 207 
anti-NF-kB1 (Cell signaling, 3035, 1:1000); anti-NF-kB2 (Cell signaling, 4882, 208 
1:1000); anti-IkBα (Cell signaling, 4814, 1:1000); anti-phospho-IkBα (Cell 209 
signaling, 9246, 1:1000); anti-p16 (Santa-Cruz, sc-759, 1:500); anti-p21 210 
(Santa-Cruz, sc-397, 1:1000); anti-SMAD2/3 (Cell signaling, 8685, 1:1000); 211 
anti-phospho-SMAD3 (Abcam, ab52903, 1:1000); anti-TGFB-induced (Cell 212 
signalling, 5601, 1:1000). Full scans of all immunoblotting is included in 213 
supplementary figure 9, including molecular weight markers. 214 
 215 
Protein from conditioned media was obtained by plating 2.5 x 106 cells in 216 
media with 2% FCS for 16 hours before filtration through a 0.22 μm filter and 217 
then centrifugation at 4000g for 20minutes through a Vivaspin 6 concentrator 218 
column (10kDa molecular weight cut-off, GE healthcare).  Coomassie staining 219 
of gels was performed as previously reported50. 220 
 221 
Hydrodynamic tail-vein injection 222 
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All animal experiments were approved by the German or UK legal authorities, 223 
and mice were kept under pathogen-free conditions in accordance with the 224 
institutional guidelines of the University of Tuebingen  or University of 225 
Cambridge.  226 
 227 
Male and female C57BL/6 mice were purchased from Charles River and 228 
injected at 5 – 8 weeks of age. Vectors for hydrodynamic injection were 229 
prepared with the Qiagen EndoFree MaxiPrep kit. Transposon-mediated gene 230 
transfer was previously described8; briefly 20μg of appropriate vector and 5μg 231 
of SB13 transposase-containing plasmid were diluted in sterile-filtered 232 
phosphate-buffered saline to a total volume of 10% of the body weight of the 233 
animal before being injected into the lateral tail vein in under 10 seconds.   234 
 235 
Immunohistochemistry 236 
Formalin fixed paraffin-embedded mouse tissues were stained with the 237 
following antibodies: anti-Notch1 (Cell signaling, 3608, 1:200); anti-Dec1 (a 238 
kind gift from Prof. Adrian Harris, 1:2000); anti-NRAS (Santa Cruz, sc-31, 239 
1:100); anti-Hes1 (Cell signaling, 11988, 1:250); anti-p21 (BD, 556431); anti-240 
CD3 (Dako, A0452, 1:1000); anti-B220 (R&D systems, MAB1217, 1:1500); 241 
anti-ki67 (Bethyl, IHC-00375, 1:1000); anti cleaved caspase 3 (Cell signaling, 242 
9664, 1:1000) after heat-induced epitope retrieval in citrate (pH6) or Tris-243 
EDTA (pH9) buffers before visualisation using the DAKO Envision kit 244 
according to manufacturers instructions and counterstaining with 245 
haematoxylin. Dual chromogenic IHC staining was performed on a Leica 246 
Bond Max (Leica) using the polymer refine detection and refine red detection 247 
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kits (Leica). For fluorescent labelling, we utilised anti-CD3 (as above) and 248 
anti-GFP (Abcam, ab13970, 1:100) with appropriate fluorochrome-tagged 249 
secondary antibodies (Life Technologies).   250 
 251 
All slides were scanned on a Leica AT2 at 20x magnification and a resolution 252 
of 0.5μm/pixel. Following digitisation, image analysis was performed using the 253 
HALO (Indicalabs), utilising the Cytonuclear v1.4 algorithm. Each stain was 254 
trained independently to provide the best accuracy for cell counting and all the 255 
slides were reviewed manually following analysis to assess accuracy. NRAS 256 
staining was counted manually from 4 random high power fields containing a 257 
median of 1457 hepatocytes (range 1304 – 1678) as described previously 8, 258 
due to problems segmenting individual cells when staining was very intense. 259 
 260 
Isolation and culture of human liver sinusoidal endothelial cells (HSEC) 261 
Tissue samples and blood samples from patients were obtained with written 262 
informed consent and with local ethics committee approval (LREC reference 263 
06/Q2702/61, Birmingham, UK and 04/Q2708/41, Birmingham, UK). Liver 264 
endothelial cells were isolated from explanted livers or donor tissue surplus to 265 
surgical requirements using a collagenase digestion (collagenase type 1a, 266 
Sigma-Aldrich) as described previously60. All tissue was collected from 267 
patients in the Liver Unit at Queen Elizabeth Hospital in Birmingham with 268 
informed consent and under local ethics committee approval. Briefly, digested 269 
tissue was placed over a 33% / 77% Percoll (Amersham Biosciences) density 270 
gradient. The endothelial cells were isolated by immunomagnetic selection 271 
using Abs against CD31 conjugated to Dynabeads (Life Technologies). The 272 
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endothelial cells were then cultured in medium composed of human 273 
endothelial basal growth medium (Life technologies), 10% AB human serum 274 
(HD supplies), 10ng/ml vascular endothelial growth factor (VEGF), and 275 
10ng/ml hepatocyte growth factor (HGF) (Peprotech). The cells were grown in 276 
collagen-coated culture flasks and were maintained at 370C in a humidified 277 
incubator with 5% CO2 until confluent.   278 
 279 
Isolation of peripheral blood lymphocytes (PBLs) 280 
PBLs were isolated as previously described61 by density gradient 281 
centrifugation over Lympholyte (VH Bio) at 800xg for 25 minutes. Harvested 282 
Lymphocytes were re-suspended in RPMI 1640 (Life Technologies) /10% fetal 283 
calf serum.   284 
 285 
Flow adhesion assay 286 
To study immune cell recruitment, HSEC were grown in Ibidi μ-slide IV flow 287 
channels (Thistle scientific, Glasgow UK) until confluent. HSEC were then 288 
cultured in conditioned media for 24 hours prior to connection to the flow 289 
system previously described35. Peripheral blood lymphocytes were perfused 290 
through the microslides over the endothelial cells at a shear stress of 0.05Pa. 291 
Phase contrast video recordings made during lymphocyte perfusion were 292 
analysed offline to determine adherence.   293 
 294 
Analysis of the IL1A locus  295 
All sequence data was obtained from IMR90 cells. IL1A is shown with both 296 
the hg19 RefSeq annotation62, and GenCode version 19 annotation63. 297 
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C/EBPβ ChIP-Seq and DNAase-Seq data are from the Encode Project39, and 298 
Histone data is from the Roadmap Epigenomics Project40. The data was 299 
visualised using the Gviz Bioconductor library. 300 
 301 
Chromatin immunoprecipitation (ChIP) 302 
ChIP was performed as described previously64 with modifications. Briefly, 303 
50ug of chromatin and 10ug of antibody (C/EBPβ: Santa Cruz sc-150) were 304 
applied to each IP. For the negative control no antibody was added to the IP. 305 
Three replicate ChIPs were carried out for each condition followed by qPCR. 306 
Primer sequences used in qPCR are as follows: 307 
IL6 (-176/-122) F (target)*: GCCATGCTAAAGGACGTCACA 308 
IL6 (-176/-122) R (target)*: GGGCTGATTGGAAACCTTATTAAGA 309 
IL6 (-1158/-1094) F (non-specific)*: CCATCCTGAGGGAAGAGGG 310 
IL6 (-1158/-1094) R (non-specific)*: CGTCGGCACCCAAGAATTT 311 
IL8 (-134/-45) F (target)*: AAGTGTGATGACTCAGGTTTGC 312 
IL8 (-134/-45) R (target)*: GCACCCTCATCTTTTCATTATG 313 
IL8 (-1324/-1240) F (non-specific)*: TCACTGCTCTGTCGTACTTTCTG 314 
IL8 (-1324/-1240) R (non-specific)*: CGCTTCTGGGCAAGTACATA 315 
IL1A proximal F (target): CTGGCAGCTTAAGCCTGAGT 316 
IL1A proximal R (target): TAAATTCCCCGTTTTGACGA 317 
IL1A distal F (target): GGCCAGAGAACTGTGAGAGG 318 
IL1A distal R (target): TGCATCAGGGCAAGTTTATG 319 
IL1A non-specific F (non-specific): AGGGGCTAGATTTGGAGAGG 320 
IL1A non-specific R (non-specific): ATTCACCCTGGAGCACAATC 321 
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* The primer sets for IL6 and IL8 were previously reported6. For IL1A 322 
‘Proximal’ (promoter) and ‘Distal’ (enhancer), qPCR primers were designed 323 
based on C/EBPβ ChIP-seq data (ENCODE). In this case, ‘non-specific’ is 324 
upstream of the IL1A promoter. The locations of the primer sets for IL1A are 325 
illustrated in Supplemental Figure 8E. 326 
 327 
Statistics and reproducibility. 328 
No statistical method was used to predetermine sample size. The 329 
experiments were not randomised and the investigators were not blinded to 330 
allocation during experiments. Unless otherwise stated, data are represented 331 
by the mean ± SEM. n values represent the number of independent 332 
experiments performed or the number of individual mice per condition. For 333 
each independent in vitro experiment a minimum number of three 334 
experiments were performed to ensure reproducibility and adequate statistical 335 
power. For in vivo experiments all conclusions were based on a minimum of 3 336 
mice per condition or time point. Analyses were conducted using Graphpad 337 
Prism 6. Student’s t-test was used for two-condition comparisons; one-way 338 
ANOVA with Dunnett’s multiple comparison test for more than 2 conditions. In 339 
the statistical analyses two-tailed tests were used throughout; a p-value of 340 
0.05 was taken as significant.  All the study data including statistical tests and 341 
exact p-values is provided in supplementary table 2.  342 
 343 
Data availability 344 
The RNA-Sequencing data generated for this study have been deposited at 345 
the Gene expression omnibus (GEO) with the accession numbers: 346 
GSE72404, GSE72407 and GSE72409. The mass spectrometry proteomics 347 
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data have been deposited to the ProteomeXchange Consortium via the 348 
PRIDE 82 partner repository with the dataset identifier PXD004168. 349 
(http://proteomecentral.proteomexchange.org). 350 
 351 
The TGFB1 signature was derived from previously published data available 352 
from GEO under accession codes GSE1249365 and GSE2966066. The 353 
CEBPB signature was derived from previously published data available from 354 
GEO under accession codes GSE47777 and GSE3083437. Chromatin 355 
immunoprecipitation datasets were obtained from GEO with the following 356 
accessions: CEBPB, GEO ID: GSM935519; DNase-Seq, GEO ID: 357 
GSM1008586; H3K27ac, GEO ID: GSM469966; H3K4me1, GEO ID: 358 
GSM521895; H3K4me3, GEO ID: GSM521901. 359 
 360 
Proteomics data from Fig. 1 and Supplementary Fig. 1 have been provided as 361 
Supplementary Table 1. All other data supporting the findings of this study are 362 
available from the corresponding author on reasonable request. 363 
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